Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ASND 
Ascendis Pharma AS (ASND)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: ASND (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
16 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $252.47
1 Year Target Price $252.47
| 12 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.99% | Avg. Invested days 39 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 12.54B USD | Price to earnings Ratio - | 1Y Target Price 252.47 |
Price to earnings Ratio - | 1Y Target Price 252.47 | ||
Volume (30-day avg) 16 | Beta 0.41 | 52 Weeks Range 118.03 - 216.45 | Updated Date 10/17/2025 |
52 Weeks Range 118.03 - 216.45 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.26 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -55.25% | Operating Margin (TTM) -33.5% |
Management Effectiveness
Return on Assets (TTM) -17.17% | Return on Equity (TTM) -818.43% |
Valuation
Trailing PE - | Forward PE 43.86 | Enterprise Value 12519835320 | Price to Sales(TTM) 25.55 |
Enterprise Value 12519835320 | Price to Sales(TTM) 25.55 | ||
Enterprise Value to Revenue 21.74 | Enterprise Value to EBITDA -20.75 | Shares Outstanding 60554408 | Shares Floating 60088745 |
Shares Outstanding 60554408 | Shares Floating 60088745 | ||
Percent Insiders 0.77 | Percent Institutions 105.86 |
Upturn AI SWOT
Ascendis Pharma AS
Company Overview
History and Background
Ascendis Pharma AS is a biopharmaceutical company founded in 2006 in Copenhagen, Denmark. It focuses on developing therapies for unmet medical needs using its TransCon technology platform. The company has evolved from a research-focused entity to a commercial-stage biopharmaceutical company with global operations.
Core Business Areas
- Endocrinology: Focuses on developing therapies for growth disorders, including hypoparathyroidism. TransCon hGH (Skytrofa) is their leading product in this segment.
- Oncology: Researching TransCon prodrugs of existing cancer therapies to improve efficacy and reduce toxicity.
- Rare Diseases: Exploring TransCon technology for developing treatments for various rare diseases.
Leadership and Structure
Jan Mikkelsen is the President and CEO. The company has a management team overseeing R&D, commercial operations, and finance. Ascendis operates with a functional organizational structure.
Top Products and Market Share
Key Offerings
- Skytrofa (TransCon hGH): A long-acting growth hormone approved for pediatric growth hormone deficiency (GHD). Market share is growing and competitive data is not fully public. Competitors include Novo Nordisk (Sogroya), Pfizer (Genotropin), and Eli Lilly (Humatrope). Revenue from this product is increasing as it penetrates the market.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with companies racing to develop and commercialize innovative therapies. The market is driven by unmet medical needs, technological advancements, and regulatory approvals.
Positioning
Ascendis Pharma AS is positioned as an innovative biopharmaceutical company utilizing its TransCon technology to develop differentiated therapies. Its competitive advantage lies in its technology platform and its ability to create long-acting versions of existing drugs.
Total Addressable Market (TAM)
The TAM for growth hormone deficiency and other endocrine disorders is substantial. Ascendis is targeting a significant portion of this market with Skytrofa and future products. The pediatric GHD market is estimated to be worth billions of dollars annually.
Upturn SWOT Analysis
Strengths
- Proprietary TransCon technology
- First FDA-approved long-acting growth hormone
- Strong intellectual property portfolio
- Experienced management team
- Expanding global presence
Weaknesses
- Dependence on Skytrofa for revenue
- High R&D expenses
- Commercialization challenges
- Relatively small company size compared to competitors
- Ongoing clinical trials carry inherent risks
Opportunities
- Expansion into new indications
- Strategic partnerships and collaborations
- Geographic expansion
- Further development of TransCon platform
- Positive clinical trial results
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Patent expiration
- Clinical trial failures
- Pricing pressures from healthcare providers
Competitors and Market Share
Key Competitors
- NVO
- PFE
- LLY
Competitive Landscape
Ascendis Pharma AS competes with established pharmaceutical companies. It is focused on its TransCon technology, but could have disadvantages as its market share is more dependent on approvals.
Growth Trajectory and Initiatives
Historical Growth: Ascendis Pharma AS has experienced significant growth since its inception, driven by the development and approval of Skytrofa. Further historical growth data would come from financials.
Future Projections: Analyst projections indicate continued revenue growth driven by Skytrofa sales and pipeline advancement. These are readily available from most financial websites.
Recent Initiatives: Recent initiatives include expanding commercial operations globally, advancing clinical trials for other TransCon products, and strengthening its intellectual property portfolio.
Summary
Ascendis Pharma AS is a growing biopharmaceutical company specializing in endocrinology, oncology and rare disease. Its strength is its proprietary TransCon technology, highlighted by Skytrofa. The company needs to commercialize in the face of giants. Continued positive clinical data is critical to maintaining investor interest.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (10K, 10Q)
- Analyst Reports
- Industry News
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and may vary. Financial data is based on publicly available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ascendis Pharma AS
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2015-01-28 | President, CEO, Member of Executive Board & Executive Director Mr. Jan Moller Mikkelsen | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1017 | Website https://ascendispharma.com |
Full time employees 1017 | Website https://ascendispharma.com | ||
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.